Iterative Health will present five abstracts at the European Crohn’s & Colitis Organization (ECCO) meeting in Berlin, Germany, Feb. 19-22, 2025.

MB310 has been developed as an oral capsule, dosed once daily, containing a defined consortium of eight live gut commensal ...

Among patients with pulmonary arterial hypertension treated with 72-week seralutinib, those deemed responders had more improved measures, according to a poster presented at the Pulmonary Vascular ...

PATNA: Bihar’s political climate is heating up ahead of assembly elections, with the main opposition Rashtriya Janata Dal ...

Patient-reported outcomes (PROs) were similar among those treated with tivozanib monotherapy and those given combination ...

Tivozanib plus nivolumab had similar patient-reported outcomes to tivozanib alone in advanced kidney cancer after prior treatment, according to the TiNivo-2 study.

Symptom scores remained stable over time, with similar QOL trends in both treatment arms.

American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA between February 13 ...

An important unanswered question is whether rechallenging patients with enfortumab vedotin plus pembrolizumab after prior ICI exposure remains effective. The authors hypothesized that enfortumab ...

A total of 37 studies included real-world OS as an outcome; in these studies, median real-world OS ranged from 9 months to 23.5 months.

Radium-223 re-treatment is safe for metastatic castration-resistant prostate cancer, per findings from the 2025 ASCO GU ...

MyCareGorithm was met with high approval from patients, companions, and physicians, with all 3 groups reporting they’d ...